Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Camp4 Therapeutics CorpCAMP · Entity 1161 | Director | June 25, 2025 | June 27, 2025 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director · President and CEO | February 12, 2025 | February 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Camp4 Therapeutics Corp
Report date June 25, 2025 · Filed June 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2035-06-24 | Direct | 9,000 |
Reported balance
After 2025-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-25 · Grant · Acquired 9,000 · Balance 9,000 F1: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date.
X4 Pharmaceuticals, Inc
Report date February 12, 2025 · Filed February 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,337,386 |
Reported balance
After 2025-02-12 transaction · row 1
1 source rowRow 1 · 2025-02-12 · Grant · Acquired 2,250,000 · Balance 3,337,386 F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2025 Filed Jun 27, 2025 20:02 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001736730-25-000054 · wk-form4_1751054523.xml · derivative · entry 1 Ragan Paula · CIK 0001769914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:08 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 2,250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-005700 · wk-form4_1739567310.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,337,386 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 23:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 76,473 | $0.45 | $34,718.74 |
DisclosureSEC source: 0001628280-25-002709 · wk-form4_1738019748.xml · nonDerivative · entry 2 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,087,386 F2 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4468 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 23:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 169,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-002709 · wk-form4_1738019748.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,163,859 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:31 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 31,897 | $0.39 | $12,583.37 |
DisclosureSEC source: 0001628280-24-048467 · wk-form4_1732051877.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 993,919 F1 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.364 to $0.41, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 20:54 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 31,897 | $0.56 | $17,926.11 |
DisclosureSEC source: 0001628280-24-042941 · wk-form4_1729112077.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,025,816 F1 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5424 to $0.5806, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 20:44 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 239,436 | $0.55 | $131,522.19 |
DisclosureSEC source: 0001628280-24-042543 · wk-form4_1728420257.xml · nonDerivative · entry 2 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,057,713 F2 · shares: These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5142 to $0.6036, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 20:44 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 532,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-042543 · wk-form4_1728420257.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,297,149 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition. Read SEC document |
| March 11, 2024 Filed Mar 11, 2024 21:20 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 49,678 | $0.88 | $43,855.74 |
DisclosureSEC source: 0001628280-24-010280 · wk-form4_1710191995.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 765,068 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.9147, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 22:09 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 1,189,578 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001628280-24-005382 · wk-form4_1708121356.xml · derivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,189,578 Underlying: Common Stock · 1,189,578 shares Expires 2034-02-13 F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 22:05 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 21,695 | $1.01 | $21,892.42 |
DisclosureSEC source: 0001628280-24-004266 · wk-form4_1707775482.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 814,746 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.97 to $1.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. Read SEC document |
| November 03, 2023 Filed Nov 3, 2023 21:26 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 39,906 | $0.90 | $35,915.40 |
DisclosureSEC source: 0001628280-23-036796 · wk-form4_1699046800.xml · nonDerivative · entry 2 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 836,441 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8043 to $0.9454, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:26 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 199,531 | $0.73 | $145,657.63 |
DisclosureSEC source: 0001628280-23-036796 · wk-form4_1699046800.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 876,347 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6835 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:58 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 532,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-036462 · wk-form4_1698958692.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,075,878 F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:11 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 6,724 | $1.92 | $12,910.08 |
DisclosureSEC source: 0001628280-23-023440 · wk-form4_1687810247.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,797 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.90 to $1.96 inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 158,604 shares represent restricted stock units. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 6,724 | $2.23 | $14,994.52 |
DisclosureSEC source: 0001628280-23-022469 · wk-form4_1686946503.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,521 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $2.14 to $2.39, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 173,548 shares represent restricted stock units. Read SEC document |
| May 31, 2023 Filed May 31, 2023 21:05 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 6,292 | $1.95 | $12,269.40 |
DisclosureSEC source: 0001628280-23-020355 · wf-form4_168556710981868.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 557,245 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.90 to $2.01, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 188,492 shares represent unvested restricted stock units. Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 20:46 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 49,678 | $0.84 | $41,729.52 |
DisclosureSEC source: 0001628280-23-007720 · wf-form4_167874040015507.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,537 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.82 to $0.89, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 202,474 shares represent restricted stock units. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 22:11 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 21,695 | $0.93 | $20,176.35 |
DisclosureSEC source: 0001628280-23-003755 · wf-form4_167649908953055.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,215 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.92 to $0.98, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 312,869 shares represent unvested restricted stock units. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:21 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Appreciation Right · Derivative | 3,438,335 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001628280-22-029259 · wf-form4_166802888801839.xml · derivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,438,335 Underlying: Common Stock · 3,438,335 shares Expires 2032-11-07 F1 · derivative.exercise_date: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of November 7, 2022, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 17:05 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 13,448 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-023324 · wf-form4_166092873647049.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,910 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.155 to $1.220, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award F4 · balance_after: Of the shares of common stock reported, 361,079 shares represent unvested restricted stock units. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 20:09 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 6,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-018043 · wf-form4_165636050509479.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,358 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.06 to $1.10, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · acquired: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award F4 · balance_after: Of the shares of common stock reported, 390,962 shares represent unvested restricted stock units. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:22 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 6,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-017436 · wf-form4_165549731713465.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,082 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.03 to $1.12, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 405,903 shares represent unvested restricted stock units. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 20:14 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 6,292 | $1.21 | $7,613.32 |
DisclosureSEC source: 0001628280-22-016336 · wf-form4_165454647747063.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,806 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.19 to $1.23, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Of the shares of common stock reported, 420,884 shares represent unvested restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 21:16 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 220,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-004517 · wf-form4_164616931615259.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,098 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Of the shares of common stock reported, 434,829 shares represent unvested restricted stock units. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 21:20 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 21,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-002506 · wf-form4_164487359327366.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,309 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.52 to $1.74, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 214,037 shares represent unvested restricted stock units. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 20:26 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 13,448 | $5.10 | $68,584.80 |
DisclosureSEC source: 0001628280-21-017331 · wf-form4_162940473895833.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,004 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $4.98 to $5.35, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 262,246 shares represent unvested restricted stock units. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 20:01 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 13,448 | $5.78 | $77,729.44 |
DisclosureSEC source: 0001628280-21-013959 · wf-form4_162646567293011.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,452 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $5.64 to $5.94, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 292,131 shares represent unvested restricted stock units. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:03 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 44,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012931 · wf-form4_162465136608750.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,900 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on June 23, 2021. One third of the shares will vest on June 23, 2022, and one third of the shares will vest on June 23, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. F2 · balance_after: Of the shares of common stock reported, 292,130 shares represent unvested restricted stock units. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:12 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 44,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012476 · wf-form4_162396430850370.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,074 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on June 15, 2021. One third of the shares will vest on June 15, 2022, and one third of the shares will vest on June 15, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. F2 · balance_after: Of the shares of common stock reported, 262,246 shares represent unvested restricted stock units. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 20:51 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,400 | $9.50 | $22,800.00 |
DisclosureSEC source: 0001628280-21-011531 · wf-form4_162266707489024.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,248 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $9.40 to $9.62, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 232,361 shares represent unvested restricted stock units. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 4,104 | $9.41 | $38,618.64 |
DisclosureSEC source: 0001628280-21-011502 · wf-form4_162266478928914.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,648 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $9.31 to $9.55, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Of the shares of common stock reported, 232,361 shares represent unvested restricted stock units. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:11 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,400 | $8.33 | $19,992.00 |
DisclosureSEC source: 0001628280-21-008873 · wf-form4_162015902838806.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,752 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $8.16 to $8.46, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 246,343 shares represent unvested restricted stock units. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 13:20 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,400 | $9.17 | $22,008.00 |
DisclosureSEC source: 0001628280-21-006624 · wf-form4_161780162022907.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,152 F1 · shares: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $8.92 to $9.40, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 246,343 shares represent unvested restricted stock units. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 20:55 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 144,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-005659 · wf-form4_161670569541218.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,552 F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 11, 2022, February 11, 2023 and February 11, 2024 subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date. F2 · balance_after: Of the shares of common stock reported, 246,343 shares represent unvested restricted stock units. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 00:05 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,400 | $9.74 | $23,376.00 |
DisclosureSEC source: 0001628280-21-003760 · wf-form4_161472988864140.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,923 F1 · shares: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $9.65 to $9.92, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 101,714 shares represent unvested restricted stock units. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 22:10 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,400 | $7.88 | $18,912.00 |
DisclosureSEC source: 0001628280-21-001402 · wf-form4_161239017942620.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,323 F1 · shares: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.82 to $7.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 101,714 shares represent unvested restricted stock units. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 13:25 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,400 | $7.00 | $16,800.00 |
DisclosureSEC source: 0001628280-21-000148 · wf-form4_160993949156703.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,723 F1 · shares: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:27 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 4,800 | $7.00 | $33,600.00 |
DisclosureSEC source: 0001628280-20-017775 · wf-form4_160919084166091.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,123 F1 · shares: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Of the shares of common stock reported, 101,714 shares represent unvested restricted stock units. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 12:53 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 1,797 | $7.00 | $12,579.00 |
DisclosureSEC source: 0001628280-20-014331 · wf-form4_160198882301435.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,923 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 20:38 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 603 | $7.00 | $4,221.00 |
DisclosureSEC source: 0001628280-20-014296 · wf-form4_160193029242006.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,720 F1 · date: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Of the shares of common stock reported, 101,714 shares represent unvested restricted stock units. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 12:35 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 8,840 | $8.04 | $71,073.60 |
DisclosureSEC source: 0001628280-20-013422 · wf-form4_159974132949074.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,323 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.56 to $8.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Of the shares of common stock reported, 101,714 shares represent unvested restricted stock units. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 21:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,400 | $7.99 | $19,176.00 |
DisclosureSEC source: 0001628280-20-013295 · wf-form4_159916768122522.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,163 F1 · shares: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.83 to $8.10, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 101,714 shares represent unvested restricted stock units. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 00:12 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 44,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-012842 · wf-form4_159779593780714.xml · nonDerivative · entry 2 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,563 F3 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on August 17, 2020. One third of the shares will vest on August 17, 2021, and one third of the shares will vest on August 17, 2022, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. F4 · balance_after: Of the shares of common stock reported, 101,713 shares represent unvested restricted stock units. Read SEC document |
| August 14, 2020 Filed Aug 19, 2020 00:12 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 44,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-012842 · wf-form4_159779593780714.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,738 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on August 14, 2020. One third of the shares will vest on August 14, 2021, and one third of the shares will vest on August 14, 2022, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. F2 · balance_after: Of the shares of common stock reported, 71,830 shares represent unvested restricted stock units. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:33 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,400 | $7.45 | $17,880.00 |
DisclosureSEC source: 0001628280-20-011642 · wf-form4_159657308658040.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,912 F1 · shares: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.41 to $7.48, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 41,946 shares represent unvested restricted stock units. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 20:24 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,400 | $9.05 | $21,720.00 |
DisclosureSEC source: 0001628280-20-010212 · wf-form4_159406704677928.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,312 F1 · shares: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $8.79 to $9.26, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 41,946 shares represent unvested restricted stock units. Read SEC document |
| June 03, 2020 Filed Jun 3, 2020 20:46 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 9,707 | $8.88 | $86,198.16 |
DisclosureSEC source: 0001628280-20-008920 · wf-form4_159121717676693.xml · nonDerivative · entry 3 Ragan Paula · CIK 0001769914 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,712 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $8.80 to $9.00, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 41,946 shares represent unvested restricted stock units. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 20:46 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 2,400 | $8.65 | $20,760.00 |
DisclosureSEC source: 0001628280-20-008920 · wf-form4_159121717676693.xml · nonDerivative · entry 2 Ragan Paula · CIK 0001769914 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,419 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $8.56 to $8.75, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Of the shares of common stock reported, 41,946 shares represent unvested restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:46 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 4,275 | $8.63 | $36,893.25 |
DisclosureSEC source: 0001628280-20-008920 · wf-form4_159121717676693.xml · nonDerivative · entry 1 Ragan Paula · CIK 0001769914 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,819 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award F3 · balance_after: Of the shares of common stock reported, 41,946 shares represent unvested restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.